Patritumab Plus Erlotinib in EGFR Wild-Type Advanced Non-Small Cell Lung Cancer: A 2-Part Phase 3 Study (HER3-Lung)

被引:0
作者
Akerley, Wallace L. [1 ]
Von Pawel, Joachim [2 ]
Moritz, Berta [3 ]
Zhang, Ling [4 ]
Macintyre, Susan [4 ]
Feng, Wenqin [4 ]
Shuster, Dale [4 ]
Chen, Shuquan [4 ]
Copigneauxl, Catherine [4 ]
Ares, Luis Paz [5 ]
机构
[1] Huntsman Canc Inst, Salt Lake City, UT USA
[2] Asklepios Fachkliniken, Gauting, Germany
[3] Cesar Cent European Soc Anticanc Drug Res, Vienna, Austria
[4] Daiichi Sankyo Pharma Dev, Edison, NJ USA
[5] Univ Hosp Virgen Del Rocio, Seville, Spain
关键词
Advanced non-small cell lung cancer; Heregulin biomarker; Phase; 3; study; Patritumab;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
P1.01-081
引用
收藏
页码:S429 / S429
页数:1
相关论文
empty
未找到相关数据